Formula: | C17H17N7 |
Molecular Weight: | 319.37 |
Rotatable Bond Donors: | 2 |
clogP: | 3.07 |
Topological Polar Surface Area: | 98.30 |
Lipinski's RO5: | MW: 319.37 HBA: 7 HBD: 3 RB: 2 LogP: 3.07 |
Rule of Three: | MW: 319.37 HBA: 7 HBD: 3 RB: 2 LogP: 3.07 |
|
DB |
---|
ZINC ID | Similarity | Structure | SDF |
---|
ZINC ID | Similarity | Structure | SDF | |
---|---|---|---|---|
ZINC20148984 | 1.0 | ZINC20148984 RDKit 3D 24 28 0 0 0 0 0 0 0 0999 V2000 -1.1701 1.9524 -2.4047 N 0 0 0 0 0 0 0 0 0 0 0 0 0.1435 1.4994 -2.2044 C 0 0 0 0 0 0 0 0 0 0 0 0 1.1253 1.9036 -3.0550 N 0 0 0 0 0 0 0 0 0 0 0 0 2.3857 1.4906 -2.8424 C 0 0 0 0 0 0 0 0 0 0 0 0 2.8293 0.7026 -1.8539 N 0 0 0 0 0 0 0 0 0 0 0 0 1.8344 0.3212 -1.0375 C 0 0 0 0 0 0 0 0 0 0 0 0 0.4937 0.6531 -1.1415 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.1340 -0.0114 -0.0392 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.5357 -0.0481 0.3459 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.5456 -0.1052 -0.6035 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.8778 -0.1663 -0.3681 N 0 0 0 0 0 0 0 0 0 0 0 0 -4.1707 -0.1857 0.9475 C 0 0 0 0 0 0 0 0 0 0 0 0 -5.4281 -0.2487 1.4827 N 0 0 0 0 0 0 0 0 0 0 0 0 -5.3615 -0.2524 2.8470 C 0 0 0 0 0 0 0 0 0 0 0 0 -4.0318 -0.1917 3.2009 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.2686 -0.1479 2.0067 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.9026 -0.0817 1.6935 C 0 0 0 0 0 0 0 0 0 0 0 0 0.7734 -0.6769 0.7000 N 0 0 0 0 0 0 0 0 0 0 0 0 1.9420 -0.4673 0.0699 N 0 0 0 0 0 0 0 0 0 0 0 0 3.1327 -1.0700 0.6177 C 0 0 0 0 0 0 0 0 0 0 0 0 4.1832 -0.0448 0.9880 C 0 0 0 0 0 0 0 0 0 0 0 0 5.4981 -0.7979 0.9353 C 0 0 0 0 0 0 0 0 0 0 0 0 5.2671 -2.0317 0.0800 C 0 0 0 0 0 0 0 0 0 0 0 0 3.8181 -1.9954 -0.3649 C 0 0 0 0 0 0 0 0 0 0 0 0 1 2 1 0 2 3 2 0 3 4 1 0 4 5 2 0 5 6 1 0 6 7 2 0 7 8 1 0 8 9 1 0 9 10 2 0 10 11 1 0 11 12 2 0 12 13 1 0 13 14 1 0 14 15 2 0 15 16 1 0 16 17 2 0 8 18 2 0 18 19 1 0 19 20 1 0 20 21 1 0 21 22 1 0 22 23 1 0 23 24 1 0 7 2 1 0 17 9 1 0 24 20 1 0 19 6 1 0 16 12 1 0 M END $$$$ |
Name | Assay stage | Target | Activity |
---|---|---|---|
Single dose inhibition of SARS-CoV-2 cytopathic effect in VeroE6 | primary assay | Organism Severe acute respiratory syndrome-related coronavirus | active |
Dose-dependent inhibition of SARS-CoV-2 cytopathic effect in VeroE6 | confirmatory assay | Organism Severe acute respiratory syndrome-related coronavirus | inactive |
Single dose inhibition of SARS-CoV-2 3CL-Pro | primary assay | Replicase polyprotein 1ab | inactive |